AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.


Read more

Targeted therapeutical areas

Read more

The American Food and Drug Administration (FDA) has granted AZP2006 the orphan drug designation...

May, 4 2017 Read more

March, 30 2017 Read more